Dear Editor,

An interesting special issue was recently published in your journal Acta Cytologica (January–February 2020) concerning the ancillary techniques in cytopathological specimens, supervised by Baloch and Gupta as guest editors [1]. In this issue, the manuscript of Zhou and Moreira stressed the importance of auxiliary techniques and special staining in pulmonary cytopathology, not only in the differential diagnosis and predictive testing of lung tumors but also in the detection of pathogenic agents of infectious disease [2].

The last few days have seen an important revelation regarding the pathophysiology of the pandemic COVID-19 infection caused by SARS-CoV-2 for severe acute respiratory syndrome coronavirus 2. This novel RNA virus is composed of RNA-dependent RNA polymerase, structural proteins (spike protein, envelope protein, membrane protein, and nucleocapsid phosphoprotein), and a set of nonstructural proteins (ORFs) [3]. The typical chest computed tomography scan features of emerging COVID-19 pneumonia included bilateral ground-glass opacities with a predominantly peripheral distribution [4].

First, a proinflammatory syndrome with notably increased levels of cytokines and chemokines (cytokine storm) or macrophage activation syndrome has been noted in hospitalized COVID-19 patients [5, 6]. More recently, bioinformatics analysis reveals that the virus causes prolonged and progressive hypoxia by binding to the heme groups of hemoglobin in red blood cells (RBCs) and inhibiting heme metabolism [7]. Consequently, the pulmonary lesions described on chest computed tomography scan are thought to be the result of the inability to exchange carbon dioxide and oxygen and the release of oxidative iron from the hemes, which overwhelm the natural defenses against pulmonary oxidative stress and may eventually result in bilateral ground-glass-like opacities in COVID-19 patients.

It is well known that RBCs carry oxygen from the lungs to other organs. They can do this with the help of hemoglobin, which is an assembly of 4 globular protein subunits called hemes. A heme group consists of an iron atom (Fe) held in a heterocyclic ring, known as porphyrin acting as its container. The Fe may be either in the ferrous (Fe2+) or in the ferric (Fe3+) state, but Fe3+ cannot bind oxygen. Oxygenation changes the electronic state of the Fe2+-heme complex. When RBCs are exposed to oxidizing agents, the heme iron in hemoglobin is oxidized from Fe2+ to Fe3+ state to form methemoglobin, which is unable to bind oxygen [8]. Thus, iron must exist in the Fe2+ state to bind oxygen. In this way, the iron ion can be safely transported by hemoglobin, but used to bind to oxygen when it reaches the pulmonary alveoli, where all the gas exchanges take place, and then goes to deliver oxygen to the other organs.

In the case of COVID-19 infection, the surface glycoprotein of the virus binds to the porphyrin of the heme. At the same time, nonstructural proteins of SARS-CoV-2 coordinate attack the heme on the 1-beta chain of hemoglobin to dissociate the iron from the porphyrin [7], and in doing so, dissociated oxidizing iron ion moves freely. Without the iron ion, hemoglobin can no longer bind to oxygen. In theory, once all hemoglobin is altered, the RBC becomes unable to carry oxygen and simply runs with the SARS-CoV-2 attached to its porphyrin. This means, on the one hand, a lack of oxygen for all the organs, and on the other hand, that released iron floats freely causing oxidative damage to these organs. This hypothesis may explain in part extrapulmonary lesions caused by COVID-19.

However, the lungs have a primary defense mechanism to maintain iron homeostasis, known as iron sequestration. The initial players in this mechanism are the alveolar macrophages that collect free radicals such as iron [9]. In COVID-19 patients, this mechanism seems to be overwhelmed by the excess of oxidizing iron and so begins the process of pulmonary oxidative stress, which leads to inflammation that is usually bilateral with COVID-19 infection.

In practice, ferric iron could be easily identified in cells and tissue samples in cytologpathology and histopathology laboratories using the routine Perls Prussian blue stain under light microscope [10]. Perls Prussian blue stain, also called as Perls stain, was described in 1867 by the pathologist Max Perls. It allows detecting the presence of iron in cells by conversion of iron to Prussian blue as shown in the following chemical formula [11]:

Ferric chloride + Potassium ferrocyanide → Ferric ferrocyanide + Potassium chloride (Prussian blue),

4FeCl3 + 3K4Fe(CN)6 → Fe4[Fe(CN)6]3 + 12KCl.

Perls stain is used to color cellular nonheme iron such as ferritin and hemosiderin but does not stain iron that is bound to porphyrin such as hemoglobin and myoglobin [12]. A combined Perls-hematoxylin-eosin stain was also proposed to easily check the presence of ferric iron in tissue sections [13]. Moreover, an immunohistochemical technique can be used to detect the presence of ferritin in tissue samples with results equivalent to Perls stain [14]. Therefore, Perls stain may be used to identify excess iron deposits caused by oxidative damage mechanism in COVID-19 patients.

The bronchoalveolar lavage (BAL) fluid is a good technique to explore alveolar macrophages, allowing for determining their percentage, size and shape, and their cytoplasm content. It also allows for making a cellular formula and searching for pathogens. Thus, LBA is considered as an important tool in the diagnosis of inflammatory, autoimmune, and infectious diseases.

In BAL fluids, hemosiderin-laden alveolar macrophages can be scored by the cytopathologist according to the hemosiderin content and the semi-quantitative method described by Golde (Golde score). Initially, the Golde score is established to assess alveolar hemorrhage in the event of capillary bed hyperpressure or alveolar wall injury; RBCs pass from the capillaries into the alveolar lumen, resulting in erythrophagocytosis. The Golde score requires a count of 100 macrophages and the establishment of a value from 0 to 4, depending on the iron density (in blue) in their cytoplasm (0 = no color in the cytoplasm, 1 = weak blue in a minor portion of cytoplasm, 2 = dark blue in a minor portion of cytoplasm or intermediate color throughout the cytoplasm, 3 = dark blue in most areas of cytoplasm, and 4 = dark blue throughout the macrophages). The result of this score depends on the sum of the number of macrophages X the value corresponding to the iron load (if counting 100 macrophages) to obtain a numerical score (Golde score: 0–20 normal, 20–70 intermediate resorption, >70 high resorption, and >100 occult alveolar hemorrhage) [15].

According to the hypothesis developed above, the alveolar macrophages collect free iron ions following heme attack by COVID-19 which separates iron from porphyrin. Consistent with this hypothesis, it can be assumed that the higher the Golde score, the more severe the hypoxia and oxidative damage.

In addition, cytological examination of BAL may help prove the alveolar damage. For example, some signs of pulmonary parenchyma aggression causing early alveolar damage such as hyaline membranes, inflammation, and desquamation of bronchiolar pneumocytes can be seen by cytological examination using standard staining protocols (Papanicolaou and May-Grünwald Giemsa stains). These pathological findings were recently described in COVID-19 patients’ tissue and autopsy reports [16, 17]. BAL fluids may reveal possible viral cytopathogenic effect not obviously shown so far for COVID-19. Moreover, the BAL when clinically indicated allows looking for coinfection by the presence of second pathogen using special stains (Gram, Giemsa, Grocott-Gomori, periodic acid-Schiff, and Ziehl-Neelsen satins) [2], which could worsen the health status of COVID-19 patients, especially in higher infectious risk patients such as HIV and diabetes patients [18, 19].

It is evident that confirmation of the utility of Golde score using Perls stain or immunocytochemical technique to detect ferric iron as an indicator of pulmonary damage in COVID-19 patients requires validation by a series of cytological examination of BAL, while taking the necessary technical precautions as fresh BAL of COVID-19 patients is considered a high-risk infectious fluid for the laboratory team. If this hypothesis is confirmed in practice, the score may need to be adapted at a later date to assess the severity of COVID-19’s damage. Obviously, careful examination of cytological specimens by using routine and special staining or ancillary technique can provide important diagnostic and prognostic information that may impact the management of COVID-19 patients.

The author declares that he has no competing interests.

The author did not receive any funding.

1.
Baloch
ZW
,
Gupta
PK
.
Cytopathology comes of age
.
Acta Cytol
.
2020
;
64
(
1–2
):
5
6
.
2.
Zhou
F
,
Moreira
AL
.
The role of ancillary techniques in pulmonary cytopathology
.
Acta Cytol
.
2020
;
64
(
1–2
):
166
74
.
3.
Mousavizadeh
L
,
Ghasemi
S
.
Genotype and phenotype of COVID-19: their roles in pathogenesis
.
J Microbiol Immunol Infect
.
2020
;
DOI
:
10.1016/j.jmii.2020.03.02230082
.
4.
Lomoro
P
,
Verde
F
,
Zerboni
F
,
Simonetti
I
,
Borghi
C
,
Fachinetti
C
, et al
COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review
.
Eur J Radiol Open
.
2020
;
7
:
100231
.
5.
Wan
S
,
Yi
Q
,
Fan
S
,
Lv
J
,
Zhang
X
,
Guo
L
, et al
Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)
.
medRxiv
.
2020
;
DOI
: .
6.
Li
X
,
Geng
M
,
Peng
Y
,
Meng
L
,
Lu
S
.
Molecular immune pathogenesis and diagnosis of COVID-19
.
J Pharm Anal
.
2020
;
10
(
2
):
102
8
.
7.
Liu
W
,
Li
H
.
COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism
.
ChemRxiv
.
2020
;
DOI
:
10.26434/chemrxiv.11938173.v8
.
8.
Sawicki
KT
,
Chang
HC
,
Ardehali
H
.
Role of heme in cardiovascular physiology and disease
.
J Am Heart Assoc
.
2015 Jan 5
;
4
(
1
):
e001138
.
9.
Philippot
Q
,
Deslée
G
,
Adair-Kirk
TL
,
Woods
JC
,
Byers
D
,
Conradi
S
, et al
Increased iron sequestration in alveolar macrophages in chronic obstructive pulmonary disease
.
PLoS One
.
2014
;
9
(
5
):
e96285
.
10.
Bunting
H
.
The histochemical detection of iron in tissues
.
Stain Technol
.
1949
;
24
(
2
):
109
15
.
11.
Drury
RAB
,
Wallington
EA
.
Carleton’s histological technique
. 5th ed.
Oxford, New York
:
Oxford University Press
;
1980
. p.
520
.
ISBN 0–19–261310–3
.
12.
Meguro
R
,
Asano
Y
,
Odagiri
S
,
Li
C
,
Iwatsuki
H
,
Shoumura
K
.
Nonheme-iron histochemistry for light and electron microscopy: a historical, theoretical and technical review
.
Arch Histology Cytol
.
2007
;
70
(
1
):
1
19
.
13.
Brundelet
PJ
.
The combined perls-hematoxylin-eosin stain
.
Stain Technol
.
1973
;
48
(
4
):
173
5
.
14.
Blissett
AR
,
Deng
B
,
Wei
P
,
Walsh
KJ
,
Ollander
B
,
Sifford
J
, et al
Sub-cellular in situ characterization of Ferritin(iron) in a rodent model of spinal cord injury
.
Sci Rep
.
2018
;
8
(
1
):
3567
.
15.
Drew
WL
,
Finley
TN
,
Golde
DW
.
Diagnostic lavage and occult pulmonary hemorrhage in thrombocytopenic immunocompromised patients
.
Am Rev Respir Dis
.
1977
;
116
(
2
):
215
21
.
16.
Xu
Z
,
Shi
L
,
Wang
Y
,
Zhang
J
,
Huang
L
,
Zhang
C
, et al
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
.
The Lancet Respir Med
.
2020 Apr
;
8
(
4
):
420
2
.
17.
Barton
LM
,
Duval
EJ
,
Stroberg
E
,
Ghosh
S
,
Mukhopadhyay
S
.
COVID-19 Autopsies, Oklahoma, USA
.
Am J Clin Pathol
.
2020 Apr 10
;
153
(
6
):
725
33
.
18.
Adepoju
P
.
Tuberculosis and HIV responses threatened by COVID-19
.
Lancet HIV
.
2020 Apr
;
87
(
5
):
e319
20
.
19.
Bloomgarden
ZT
.
Diabetes and COVID-19
.
J Diabetes
.
2020 Apr
;
12
(
4
):
347
8
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.